Biofortuna Limited, the specialist laboratory services and diagnostic CDMO, has completed the acquisition of Colibri Scientific Limited. The move underlines Biofortuna’s commitment to supporting life-changing research and development across the healthcare and life sciences sectors.
This acquisition brings industry-leading expertise in clinical trial sample operations, further strengthening Biofortuna’s service offering and accelerating the growth of its laboratory and sample management services.
Colibri Scientific specialises in the management, storage, and coordination of biological samples for clinical trials, supporting pharmaceutical and biotechnology companies with the reliable, compliant, and efficient handling of critical trial materials. These services play a vital role in ensuring the integrity and traceability of clinical samples throughout the therapeutic development lifecycle.
The enlarged group will provide an enhanced portfolio of in-house laboratory services. Customers will continue to benefit from the same highly skilled, personalised approach to clinical trial management, while gaining access to greater capacity and increased support for complex trials
Dr Nick Ash, CEO of Biofortuna said: “Colibri Scientific is an excellent business that aligns perfectly with our laboratory analysis and biobanking services. Together, we create a more competitive offering across sample management, storage, and bioanalysis. This acquisition strengthens our capabilities and reflects our strong momentum as we scale our services. I am delighted to welcome the Colibri Scientific team and their customers to Biofortuna.”
Sue Keeler, Colibri Scientific Founder and Head of Clinical Operations at Biofortuna added: “Joining Biofortuna allows us to expand our integrated services across the therapeutic development pathway, while retaining the agility and flexibility our customers value. Together, we can enhance our offering and support more complex, larger-scale international clinical studies.”
Notes to Editors
About Biofortuna
Biofortuna is a specialist laboratory services and diagnostic Contract Development and Manufacturing Organisation (‘CDMO’). Biofortuna provide cell line QC testing, custom assay development, contract manufacturing and sample management services to empower their global partners in healthcare, biotechnology and academia to advance innovative life sciences and diagnostic applications in health and wellbeing.
The Company is ISO 13485 and ISO 17025 accredited, FDA registered, accredited by UK Government Ministry of Justice for DNA Relationship Testing and licensed by the Human Tissue Authority, the Animal and Plant Agency and the Home Office.
Comments are closed.
